Company news

Stoke Therapeutics, Inc. news in 2020

Stoke Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Stoke Therapeutics to Present at the Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference

December 3, 2020

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

December 3, 2020

Stoke Therapeutics Announces Presentations Related to the Company’s Work in Dravet Syndrome at the American Epilepsy Society 2020 Virtual Annual Meeting

November 24, 2020

Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

November 23, 2020

Stoke Therapeutics Announces Pricing of $97.5 Million Public Offering

November 18, 2020

Stoke Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

November 8, 2020

Stoke Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference

November 1, 2020

Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome

October 6, 2020

Stoke Therapeutics to Present at Cantor Virtual Global Healthcare Conference

September 8, 2020

Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model

August 25, 2020

Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D., to its Board of Directors

August 16, 2020

Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein Expression

July 8, 2020

Stoke Therapeutics Appoints Julie Anne Smith to its Board of Directors

June 3, 2020

Stoke Therapeutics Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency, the Primary Cause of the Most Common Inherited Optic Nerve Disorder

May 11, 2020

Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates

March 22, 2020

Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference

February 23, 2020

Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference

January 6, 2020

Decks in 2020